In ALK-rearranged PDTOs, a multiparametric analysis including cancer stage and tumor cell proliferation rate showed that an ALK-directed drug response could be classified according to both the rearrangement status and the clinical data, highlighting its potential in the decision-making process [43]. This evidence concerns the gene ALK and cancer.